{"id":33342,"date":"2023-07-09T12:28:59","date_gmt":"2023-07-09T16:28:59","guid":{"rendered":"https:\/\/ifintechworld.com\/uncategorized\/factbox-companies-in-alzheimers-race-after-us-nod-for-eisai-biogen-drug\/"},"modified":"2023-07-09T12:29:00","modified_gmt":"2023-07-09T16:29:00","slug":"factbox-companies-in-alzheimers-race-after-us-nod-for-eisai-biogen-drug","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=33342","title":{"rendered":"Factbox-Companies in Alzheimer’s race after US nod for Eisai\/Biogen drug"},"content":{"rendered":"
\n
\n

\u00a9 Reuters. FILE PHOTO: The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via REUTERS\/File Photo<\/span>
\n<\/i>\n<\/div>\n

(Reuters) – Eisai Co (OTC:) Ltd and Biogen Inc (NASDAQ:)’s Leqembi emerged as the first Alzheimer’s treatment to win the U.S. Food and Drug Administration’s standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past.<\/p>\n

The following is a list of companies that are currently developing treatments that aim to modify the memory-robbing disease:<\/p>\n

Company Drug or Stage of Mechanism<\/p>\n

Therapy development &<\/p>\n

indication<\/p>\n

Eli Lilly (NYSE:) donanemab Designed to<\/p>\n

and Co Late-stage trial target toxic<\/p>\n

for early protein plaque<\/p>\n

Alzheimer\u2019s in the brain<\/p>\n

known as<\/p>\n

beta-amyloid<\/p>\n

and remove<\/p>\n

brain plaques<\/p>\n

to slow<\/p>\n

cognitive<\/p>\n

decline<\/p>\n

BioVie Inc NE3107 An oral small<\/p>\n

Late-stage trial molecule that<\/p>\n

for mild to aims to inhibit<\/p>\n

moderate neuroinflammati<\/p>\n

Alzheimer\u2019s on and insulin<\/p>\n

resistance<\/p>\n

AB Science masitinib An oral<\/p>\n

SA Late-stage study tyrosine kinase<\/p>\n

for inhibitor that<\/p>\n

mild-to-moderate targets immune<\/p>\n

Alzheimer\u2019s cells<\/p>\n

responsible for<\/p>\n

neuroinflammati<\/p>\n

on<\/p>\n

Annovis buntanetap An<\/p>\n

Bio Inc Mid-to-late-stage orally-administ<\/p>\n

trial for moderate ered small<\/p>\n

Alzheimer’s molecule<\/p>\n

inhibitor of<\/p>\n

several<\/p>\n

neurotoxic<\/p>\n

proteins<\/p>\n

Cognition CT1812 Oral drug<\/p>\n

Therapeuti Mid-stage trial designed to<\/p>\n

cs Inc for bind to a<\/p>\n

mild-to-moderate specific<\/p>\n

Alzheimer\u2019s receptor in<\/p>\n

brain cells,<\/p>\n

which mediates<\/p>\n

the attachment<\/p>\n

of beta-amyloid<\/p>\n

Coya COYA 301 Designed to<\/p>\n

Therapeuti Mid-stage trial inhibit<\/p>\n

cs Inc for molecules<\/p>\n

mild-to-moderate responsible for<\/p>\n

Alzheimer\u2019s neuroinflammati<\/p>\n

on and improve<\/p>\n

cognitive<\/p>\n

function<\/p>\n

Actinogen xanamem Blocks<\/p>\n

Medical Mid-stage trial production of a<\/p>\n

Limited for mild-moderate hormone linked<\/p>\n

Alzheimer’s to stress<\/p>\n

called cortisol<\/p>\n

inside brain<\/p>\n

cells and is<\/p>\n

associated with<\/p>\n

cognitive<\/p>\n

impairment<\/p>\n

AC Immune ACI-24.060 Early- An<\/p>\n

SA -to-mid stage antibody-based<\/p>\n

trial for immunotherapy<\/p>\n

Alzheimer\u2019s vaccine<\/p>\n

designed to<\/p>\n

target beta<\/p>\n

amyloid plaques<\/p>\n

Biogen Inc BIIB080 An antisense<\/p>\n

Mid-stage trial oligonucleotide<\/p>\n

for early-stage therapy<\/p>\n

Alzheimer\u2019s directed<\/p>\n

against “tau”<\/p>\n

proteins<\/p>\n

Longeveron lomecel-B A cell therapy<\/p>\n

Inc Mid-stage trial designed to<\/p>\n

for mild stimulate<\/p>\n

Alzheimer\u2019s neuroregenerati<\/p>\n

on and prevent<\/p>\n

disease<\/p>\n

progression<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a9 Reuters. FILE PHOTO: The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via REUTERS\/File Photo (Reuters) – Eisai Co (OTC:) Ltd and Biogen Inc (NASDAQ:)’s Leqembi emerged as the first Alzheimer’s treatment to win the U.S. Food and Drug Administration’s standard approval on Thursday, […]<\/p>\n","protected":false},"author":1,"featured_media":33343,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[1],"tags":[83],"class_list":["post-33342","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-uncategorized","tag-featured","post_format-post-format-video"],"yoast_head":"\nFactbox-Companies in Alzheimer's race after US nod for Eisai\/Biogen drug | iFintechWorld<\/title>\n<meta name=\"description\" content=\"\u00a9 Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=33342\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Factbox-Companies in Alzheimer's race after US nod for Eisai\/Biogen drug | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"\u00a9 Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=33342\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-09T16:28:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-09T16:29:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/07\/Biogen_800x533_L_1623307766.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=33342#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=33342\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Factbox-Companies in Alzheimer’s race after US nod for Eisai\/Biogen drug\",\"datePublished\":\"2023-07-09T16:28:59+00:00\",\"dateModified\":\"2023-07-09T16:29:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=33342\"},\"wordCount\":360,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=33342#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=33342\",\"url\":\"https:\/\/ifintechworld.com\/?p=33342\",\"name\":\"Factbox-Companies in Alzheimer's race after US nod for Eisai\/Biogen drug | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-07-09T16:28:59+00:00\",\"dateModified\":\"2023-07-09T16:29:00+00:00\",\"description\":\"\u00a9 Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=33342#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=33342\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=33342#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Factbox-Companies in Alzheimer’s race after US nod for Eisai\/Biogen drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Factbox-Companies in Alzheimer's race after US nod for Eisai\/Biogen drug | iFintechWorld","description":"\u00a9 Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=33342","og_locale":"en_US","og_type":"article","og_title":"Factbox-Companies in Alzheimer's race after US nod for Eisai\/Biogen drug | iFintechWorld","og_description":"\u00a9 Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via","og_url":"https:\/\/ifintechworld.com\/?p=33342","og_site_name":"iFintechWorld","article_published_time":"2023-07-09T16:28:59+00:00","article_modified_time":"2023-07-09T16:29:00+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/07\/Biogen_800x533_L_1623307766.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=33342#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=33342"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Factbox-Companies in Alzheimer’s race after US nod for Eisai\/Biogen drug","datePublished":"2023-07-09T16:28:59+00:00","dateModified":"2023-07-09T16:29:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=33342"},"wordCount":360,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=33342#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=33342","url":"https:\/\/ifintechworld.com\/?p=33342","name":"Factbox-Companies in Alzheimer's race after US nod for Eisai\/Biogen drug | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-07-09T16:28:59+00:00","dateModified":"2023-07-09T16:29:00+00:00","description":"\u00a9 Reuters. FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai\/Handout via","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=33342#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=33342"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=33342#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Factbox-Companies in Alzheimer’s race after US nod for Eisai\/Biogen drug"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/33342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33342"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/33342\/revisions"}],"predecessor-version":[{"id":33344,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/33342\/revisions\/33344"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/33343"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}